Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Collagenase Santyl Clear all
Not listed Phase 4 Interventional

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Xiaflex® 0.58 mg
Drug
Lead sponsor
Manhattan Medical Research Practice, PLLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 17, 2026, 7:53 PM EDT
Terminated Not applicable Interventional

MEDIHONEY® Gel Versus Collagenase for Wound Debridement

NCT02482948
View directory record Official record
Conditions
Ulcer, Wounds
Interventions
Active Leptospermum Honey (Medihoney), Collagenase
Device · Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

NCT01674634
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
XIAFLEX / XIAPEX
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effectiveness of Splinting After Collagenase Injection

NCT04874870
View directory record Official record
Conditions
Dupuytren Contracture, Dupuytren's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex], Xiaflex + Hand-Based Custom Orthosis
Drug · Combination Product
Lead sponsor
Foundation for Orthopaedic Research and Education
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

NCT00528606
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

NCT04786106
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery, RestoreX Penile Traction Device
Drug · Procedure · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.

NCT05026216
View directory record Official record
Conditions
Cellulite
Interventions
Qwo
Drug
Lead sponsor
DMR Research, PLLC
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Sep 17, 2026, 7:53 PM EDT
Withdrawn Not applicable Interventional

Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction

NCT05646602
View directory record Official record
Conditions
Peyronie Disease, Penile Curvature, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Duolith SD1 T-TOP
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 17, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease

NCT06065436
View directory record Official record
Conditions
Peyronie Disease, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Storz Duolith LiSWT
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

NCT02193828
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Tucson, Arizona • Encinitas, California • Greenbrae, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease

NCT00755222
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530
View directory record Official record
Conditions
Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528424
View directory record Official record
Conditions
Advanced Dupuytren's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00078390
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer, Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer
Interventions
S-3304, Chemo-irradiation
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
La Jolla, California • Washington D.C., District of Columbia • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture

NCT00528931
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 4 Interventional Results available

Using Santyl on Diabetic Foot Ulcers

NCT01408277
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions
Santyl, Control
Biological · Procedure
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Phoenix, Arizona • Tucson, Arizona • Southfield, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221597
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Homewood, Alabama • Phoenix, Arizona • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 7:53 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers

NCT01208220
View directory record Official record
Conditions
Pressure Ulcer, Soft Tissue Necrosis Lower Limb
Interventions
Negative Pressure Wound Therapy, Collagenase Ointment
Device · Biological
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease

NCT00004409
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase
Drug
Lead sponsor
State University of New York
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
2
States / cities
Palo Alto, California • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 17, 2026, 7:53 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture

NCT01226121
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Clostridial collagenase injectable
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Indianaplis, Indiana • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 17, 2026, 7:53 PM EDT
Completed No phase listed Observational

SSD vs Collagenase in Pediatric Burn Patients

NCT00787592
View directory record Official record
Conditions
Burns
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Months to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 17, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

Administration of Two Injections for Multiple Dupuytren's Contractures

NCT01407068
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
AA4500 collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 7:53 PM EDT